产品
编 号：F546072
分子式：C166H273N45O54S2
分子量：3827.34
分子式：C166H273N45O54S2
分子量：3827.34
产品类型
规格
价格
是否有货
结构图
CAS No: 99658-03-4
产品详情
生物活性：
α-Helical Corticotropin Releasing Factor (9-41) is a corticotropin releasing factor (CRF) antagonist. α-Helical Corticotropin Releasing Factor (9-41) decreases plasma growth hormone (GH) values in vivo.
体内研究：
α-Helical Corticotropin Releasing Factor (9-41) (10 μg; the third or lateral ventricle of the brain injection; once) significantly decreases plasma GH values.α-Helical Corticotropin Releasing Factor (9-41) (100 ng/kg; i.c.v. once) affects rhlL-1/β-induced enhancement of the splenic sympathetic activity.Animal Model:Adult Sprague-Dawley rats
Dosage:10 μg
Administration:The third or lateral ventricle of the brain injection; 10 μg once
Result:Abolished the 10 min electroshocks-produced the decreasing of plasma GH levels by injected into the third or lateral ventricle of the brain 45 min before exposure to stress.
Animal Model:Adult Sprague-Dawley rats with immunity of endogenous somatostatin (SS)
Dosage:10 μg
Administration:Lateral ventricle brain injection; 10 μg once
Result:Showed no effect on plasma GH values in rats whose endogenous SS had been immunoneutralized, but did interfere with the stimulatory effect of GH-releasing factor (GRF).
Animal Model:Male Wistar rats with rhlL-1/β injection
Dosage:100 ng/kg
Administration:Intracerebroventricularly injection; 100 ng/kg once
Result:Completely blocked the rhlL-1/β-induced enhancement of the splenic sympathetic activity, but failed to alter the enhancement of nociceptive behaviors caused by rhlL-1/β.
α-Helical Corticotropin Releasing Factor (9-41) is a corticotropin releasing factor (CRF) antagonist. α-Helical Corticotropin Releasing Factor (9-41) decreases plasma growth hormone (GH) values in vivo.
体内研究：
α-Helical Corticotropin Releasing Factor (9-41) (10 μg; the third or lateral ventricle of the brain injection; once) significantly decreases plasma GH values.α-Helical Corticotropin Releasing Factor (9-41) (100 ng/kg; i.c.v. once) affects rhlL-1/β-induced enhancement of the splenic sympathetic activity.Animal Model:Adult Sprague-Dawley rats
Dosage:10 μg
Administration:The third or lateral ventricle of the brain injection; 10 μg once
Result:Abolished the 10 min electroshocks-produced the decreasing of plasma GH levels by injected into the third or lateral ventricle of the brain 45 min before exposure to stress.
Animal Model:Adult Sprague-Dawley rats with immunity of endogenous somatostatin (SS)
Dosage:10 μg
Administration:Lateral ventricle brain injection; 10 μg once
Result:Showed no effect on plasma GH values in rats whose endogenous SS had been immunoneutralized, but did interfere with the stimulatory effect of GH-releasing factor (GRF).
Animal Model:Male Wistar rats with rhlL-1/β injection
Dosage:100 ng/kg
Administration:Intracerebroventricularly injection; 100 ng/kg once
Result:Completely blocked the rhlL-1/β-induced enhancement of the splenic sympathetic activity, but failed to alter the enhancement of nociceptive behaviors caused by rhlL-1/β.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备